We are live on !
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
-$303M
(-6.2%)
Cap. Flow
-$726M
Cap. Flow % of AUM
Cap. Flow %
-15.73%
Top 10 Holdings %
Top 10 Hldgs %
43.33%
Holding
116
New
19
Increased
32
Reduced
19
Closed
31
Avg Time Held
Equity + Options
0.8
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.4
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Universal Health Services
UHS
|
+$97.5M |
| 2 |
Surgery Partners
SGRY
|
+$75.3M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$60M |
| 4 |
Prothena Corp
PRTA
|
+$57.7M |
| 5 |
argenx
ARGX
|
+$49.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$280M |
| 2 |
Biogen
BIIB
|
+$160M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$120M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$104M |
| 5 |
Humana
HUM
|
+$103M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.28% |
| 2 | Miscellaneous | 7.3% |
| 3 | Financials | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Altimmune
ALT
$428M
| $65.6M | 1.42% |
3,990,000
+1,306,000
| +49% | +$14.7M |
2021 Q3
5 quarters
|
|
27
Revolution Medicines
RVMD
$38.1B
| $59M | 1.28% |
2,475,000
+153,800
| +7% | +$3.27M |
2022 Q2
2 quarters
|
|
28
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $58.8M | 1.27% |
299,000
-132,800
| -31% | -$28.5M |
2022 Q2
2 quarters
|
|
29
Arrowhead Research
ARWR
$7.9B
| $55.8M | 1.21% |
1,375,000
+119,626
| +10% | +$3.96M |
2021 Q2
6 quarters
|
|
30
Axsome Therapeutics
AXSM
$8.23B
| $51.7M | 1.12% |
670,000
-868,600
| -56% | -$51.9M |
2022 Q3
1 quarter
|
|
|
31
Vertex Pharmaceuticals
VRTX
$127B
| $49.7M | 1.08% |
172,000
-340,800
| -66% | -$104M |
2020 Q4
8 quarters
|
|
32
Legend Biotech
LEGN
$3.59B
| $48.4M | 1.05% |
+970,000
| New | +$47M |
2022 Q4
0 quarters
|
|
33
DELISTED
Kezar Life Sciences
KZR
| $47.7M | 1.03% |
678,240
+136,800
| +25% | +$10.1M |
2021 Q3
5 quarters
|
|
34
Pliant Therapeutics
PLRX
$55.7M
| $43.3M | 0.94% |
2,240,400
+259,300
| +13% | +$5.42M |
2022 Q3
1 quarter
|
|
35
DELISTED
Ventyx Biosciences
VTYX
| $42.1M | 0.91% |
+1,285,000
| New | +$38.1M |
2022 Q4
0 quarters
|
|
36
Icon
ICLR
$13.1B
| $41.8M | 0.9% |
+215,000
| New | +$42.6M |
2022 Q4
0 quarters
|
|
37
Quest Diagnostics
DGX
$25.9B
| $40.4M | 0.87% |
+258,000
| New | +$37.1M |
2022 Q4
0 quarters
|
|
38
Bio-Rad Laboratories Class A
BIO
$9.46B
| $38.8M | 0.84% |
92,200
-52,600
| -36% | -$21.2M |
2022 Q3
1 quarter
|
|
|
BLU
39
DELISTED
BELLUS Health Inc.
BLU
| $37.8M | 0.82% |
4,599,998
+253,298
| +6% | +$2.36M |
2020 Q4
8 quarters
|
|
40
Tenet Healthcare
THC
$21.5B
| $35M | 0.76% |
+717,300
| New | +$33.2M |
2022 Q4
0 quarters
|
|
41
Karyopharm Therapeutics
KPTI
$8.85M
| $32.8M | 0.71% |
+642,261
| New | +$44.5M |
2022 Q4
0 quarters
|
|
42
BioNTech
BNTX
$22B
| $32.4M | 0.7% |
+215,400
| New | +$33.1M |
2022 Q4
0 quarters
|
|
43
DELISTED
Verve Therapeutics
VERV
| $30.3M | 0.66% |
1,565,000
+522,294
| +50% | +$13.8M |
2022 Q3
1 quarter
|
|
44
Rocket Pharmaceuticals
RCKT
$239M
| $29.9M | 0.65% |
+1,527,087
| New | +$28.1M |
2022 Q4
0 quarters
|
|
45
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $26.7M | 0.58% |
504,000
-898,500
| -64% | -$45M |
2022 Q2
2 quarters
|
|
46
Arcutis Biotherapeutics
ARQT
$3.62B
| $26M | 0.56% |
1,755,000
+960,500
| +121% | +$16.8M |
2022 Q3
1 quarter
|
|
|
RXDX
47
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $22.4M | 0.49% |
+204,000
| New | +$13.2M |
2022 Q4
0 quarters
|
|
48
Intellia Therapeutics
NTLA
$1.6B
| $22.3M | 0.48% |
638,200
-360,900
| -36% | -$17.2M |
2022 Q1
3 quarters
|
|
49
Vir Biotechnology
VIR
$1.69B
| $21.5M | 0.47% |
+850,000
| New | +$20.8M |
2022 Q4
0 quarters
|
|
50
Phathom Pharmaceuticals
PHAT
$560M
| $21.3M | 0.46% |
1,900,000
-6,800
| -0.4% | -$70.1K |
2021 Q4
4 quarters
|
|
Similar funds
RIP
PWS
LWP
FGA
BVC
Avidity Partners Management's Q4 2022 Portfolio in Review
As of Q4 2022, Avidity Partners Management held 116 positions worth $4.62B, down 6.2% from $4.92B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Avidity Partners Management withdrew a net $726M in Q4 2022, closing 31 positions and reducing 19 holdings. Its most notable exit was Biogen, an estimated $160M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Avidity Partners Management opened a new position in Universal Health Services worth $116M.
- Avidity Partners Management's largest Q4 2022 buy was Universal Health Services: 825,600 shares worth $116M.
- Avidity Partners Management added most to Surgery Partners in Q4 2022, an estimated $75.3M increase.
- Avidity Partners Management's biggest Q4 2022 reduction was Eli Lilly, cutting an estimated $280M.
- Avidity Partners Management fully exited Biogen in Q4 2022, selling an estimated $160M.
- Avidity Partners Management's ten largest holdings make up 43% of its $4.62B portfolio in Q4 2022.
- Avidity Partners Management opened 19 new positions and closed 31 in Q4 2022.
- Avidity Partners Management's portfolio value fell 6.2% quarter-over-quarter to $4.62B.
Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.